Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PKX 001

Next Previous
Drug Profile

PKX 001

Alternative Names: AAGP; PKX-001

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institut National des Sciences Appliquees de Rouen; ProtoKinetix
  • Developer ProtoKinetix; University of Alberta
  • Class Antihyperglycaemics; Cardiovascular therapies; Eye disorder therapies; Glycopeptides; Glycoproteins; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers; Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Type 1 diabetes mellitus
  • Preclinical Age-related macular degeneration; Cardiovascular disorders; Dry eyes

Most Recent Events

  • 30 May 2025 PKX 001 is still in phase I trial for Type-1 diabetes mellitus (ProtoKinetix pipeline, May 2025)
  • 30 May 2025 PKX 001 is still in preclinical development for Cardiovascular-disorders, Age-related-macular-degeneration and Dry-eyes in Canada (ProtoKinetix pipeline, May 2025)
  • 07 May 2025 University of Alberta completes a phase I trial in Type-1 diabetes mellitus in Canada (NCT03073577)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top